Swiss longevity biotech startup Timeline bags €60.6M from L’Oréal, Nestlé, others

Swiss longevity biotech startup Timeline bags €60.6M from L’Oréal, Nestlé, others

Lausanne-based Timeline, a consumer health biotech company developing healthy ageing and longevity solutions, has secured $66M (approximately €60.62M) in an oversubscribed Series D round of funding. The investment was led by L’Oréal’s venture capital fund, BOLD (Business Opportunities for L’Oréal Development) and Nestlé. Investors supporting Timeline BOLD signals confidence in Timeline’s proprietary Mitopure technology for promoting longer, healthier lives. Barbara Lavernos, Deputy CEO and in charge of Research, Innovation and Technology at L’Oréal says, “Longevity is about living healthier for longer and L’Oréal has been working for a decade to understand and anticipate what this could mean for beauty.” “Longevity is a new definition of beauty, at the intersection of different scientific disciplines, from decoding biological markers to analysing external exposure. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.” Anna Mohl, CEO of Nestlé Health Science adds, “We have been an investor in Timeline since 2019 and continue to be very impressed with the team and stand behind the exponential potential that the Mitopure technology holds for nutrition to help people age better.” “We’re excited to have L’Oréal join as an investor and strategic partner to bring this technology to new heights and extend its applications.” Brief about Timeline Timeline, under parent company Amazentis, claims to pioneer Swiss health science with its Mitopure ingredient for longevity. Utilising over a decade of ageing science expertise, Timeline integrates Mitopure into advanced nutritional supplements and skin health products. With extensive research, clinical studies, patents, and Nestlé Health Science’s investment since 2019, Timeline aims to extend the human health span for a future of longer, healthier lives. Capital utilisation Mitopure, supported by 15+ years of research, clinically targets cellular longevity by recycling and renewing mitochondria. Optimal mitochondrial function sustains cellular energy, benefiting muscle strength, cognition, immune resilience, skin vitality, and overall healthspan. The raised funds will propel Timeline into a leading longevity consumer health brand. Their focus includes expanding science, product categories, and market presence across the food, beauty, and health sectors. Patrick Aebischer, co-founder and Chairman of Timeline says, “This strategic collaboration reflects the breakthrough multidimensional approach that we’ve always believed is necessary to make meaningful advancements for longevity and healthspan. “I want to thank L’Oréal, Nestlé and our longstanding investors for their commitment to longevity solutions rooted in the highest level of science.”

This content was originally published here.